Factor VII Activating Protease (FSAP) Inhibits the Outcome of Ischemic Stroke in Mouse Models
Posted by Adam Awdish on
Mouse Total Fibrinogen ELISA Kit from Innovative Research was used in the following study:
Factor VII Activating Protease (FSAP) Inhibits the Outcome of Ischemic Stroke in Mouse Models
Jeong Yeon Kim, Dipankar Manna, Trygve B. Leergaard, Sandip M. Kanse
bioRxiv
January 12, 2022
Factor VII activating protease (FSAP) is a serine protease associated with cell adhesion, and patients diagnosed with the Marburg I (MI) single nucleotide polymorphism (SNP) have an increased chance of stroke due to inactivation of the FSAP enzyme. Observations in both human patients that have suffered a stroke and in vitro mouse models have shown raised plasma FSAP levels and data from in vitro mouse models suggests that FSAP promotes fibrinolysis among other cytotoxicity-decreasing mechanisms. Since this is the desired result following treatment for a stroke, this study looked to investigate the effect the recombinant serine protease domain of FSAP (FSAP-SPD) has on ischemic strokes in mouse models.
Researchers observed faster clotting in a thromboembolic stroke model, indicating pro-coagulant effects resulting from the treatment. Further, when co-treated with tissue plasminogen activator (tPA) there appeared to be a decreased risk of negative outcomes in stroke treatment, making this a promising new method of treatment for ischemic stroke.
Related products available from Innovative Research also include: